Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy (Adv. Sci. 40/2024)

Nanovaccine In article number 2404159, Helena F. Florindo, Ronit Satchi-Fainaro, and co-workers describe the development of a next-generation thermostable multi-epitope mannosylated nanovaccine administered intranasally. This innovative nanovaccine generates mucosal immunity while regulating PD-1/PD-L1 axis within the DC-T cell interface, coordinating CD4 and CD8 T-cell immunities and activating robust neutralizing antibody responses against SARS-CoV-2. This cover artwork highlights the main features of our novel delivery system: The sugar-coated train carries the SARS-CoV-2 peptides cargo, while speeding on PD-L1 siRNA tracks through the nose caves to reach the final destination- an effector and protective immunity. Illustration credit: Sharon Amlani.